Craig-Hallum Maintains Buy on Myriad Genetics, Raises Price Target to $8

Benzinga Newsdesk www.benzinga.com Positive 51.5%

Neg 0% Neu 0% Pos 51.5%

Craig-Hallum analyst John Wilkin maintains Myriad Genetics (NASDAQ:MYGN) with a Buy and raises the price target from $4 to $8.